{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-22-017024","form_type":"8-K/A","ticker":"NXL","cik":"0001527352","company_name":"Nexalin Technology, Inc.","filed_at":"2022-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.025649+00:00","generated_at":"2026-06-23T08:30:34.028294+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nexalin Technology closes $9.6M IPO; shares and warrants begin trading on Nasdaq","bullets":["Closed IPO of 2,315,000 units at $4.15/unit (1 share + 1 warrant); gross proceeds $9.6M, net $8.7M.","Warrants exercisable at $4.15 for 3 years (until Sept 19, 2025); redeemable at $0.01 if stock >$12.45 for 20 of 30 days.","Maxim Group partially exercised overallotment, purchasing 347,250 warrants.","Gen-2 neurostimulation device approved in China by NMPA for insomnia and depression.","Shares (NXL) and warrants (NXLIW) began trading on Nasdaq on Sept 16, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-22-017024","json":"https://secwatch.observer/filing/0001829126-22-017024.json","markdown":"https://secwatch.observer/filing/0001829126-22-017024.md","text":"https://secwatch.observer/filing/0001829126-22-017024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527352/000182912622017024/0001829126-22-017024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527352/000182912622017024/nexalintech_8ka1.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:30:34.028294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}